title: Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?
abstract: The objective of the present study was to analyze whether veno-occlusive disease (VOD) is based on specific findings or whether this syndrome is the exacerbation of changes in hemostatic parameters that develop following hematopoietic stem cell transplantation (HSCT). 40 patients undergoing HSCT were enrolled (6 allogeneic bone marrow transplantation and 34 peripheral stem cell rescue-2 allogeneic, 32 autologous). Measurements of hemostatic parameters (endothelial, hypercoagulability and fibrinolytic markers) were obtained prior to chemotherapy and weekly thereafter for 3 weeks. The incidence of VOD was 15%. HSCT showed a state of moderate hypercoagulability (increase of thrombin-antithrombin complex and fibrinogen, and decrease of Factor VII, Protein C, and antithrombin-III), probably as a consequence of marked endothelial damage (increase of von Willebrand Factor and tissue plasminogen activator). All these alterations create a potentially prothrombotic state, more pronounced in VOD. The decreasing incidence of VOD and the moderate disease in all patients suggest that increasing improvements in transplant strategies have reduced the risk and severity of a syndrome that at the beginning of the transplantation era was a leading cause of morbidity/mortality.
authors.affiliation: Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Villalón
authors.forename: A G
authors.initials: AG
authors.lastname: Avello
authors.forename: J
authors.initials: J
authors.lastname: César
authors.forename: J
authors.initials: J
authors.lastname: Odriozola
authors.forename: J
authors.initials: J
authors.lastname: López
authors.forename: J P
authors.initials: JP
authors.lastname: Oteyza
authors.forename: J G
authors.initials: JG
authors.lastname: Laraña
authors.forename: A
authors.initials: A
authors.lastname: Cantalapiedra
authors.forename: J L
authors.initials: JL
authors.lastname: Navarro
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000502:physiology; D001779:Blood Coagulation Factors / Q000378:metabolism; D002779:Cholestasis / Q000097:blood; D003937:Diagnosis, Differential; D004730:Endothelium, Vascular / Q000293:injuries / Q000503:physiopathology; D005260:Female; D005342:Fibrinolysis / Q000502:physiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006487:Hemostasis / Q000502:physiology; D020141:Hemostatic Disorders / Q000503:physiopathology*; D006801:Humans; D015994:Incidence; D007677:Kidney Function Tests; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013577:Syndrome; D019172:Transplantation Conditioning; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000175:diagnosis* / Q000503:physiopathology
chemical_list: D015415:Biomarkers; D001779:Blood Coagulation Factors